Cross Immunity of a Sonicated Trivalent Avian Colibacillosis Vaccine to Pathogenic Escherichia coli O26 and O78 Strains in Broiler Chickens

Document Type : Research Article

Authors

Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran.

Abstract

Colibacillosis outbreaks are a global issue affecting the poultry industry. There is no cross-immunity among the strains of APEC. If a vaccine induces cross-immunity, it will play a key role in preventing colibacillosis. Herein, a sonicated trivalent colibacillosis vaccine containing O78:K80, O2:K1, and O1:K1 serotypes, with Alum as an adjuvant, was used to assess cross-immunity against E. coli O26. Ninety-six broiler chickens were randomly assigned to four groups: Group A was vaccinated and exposed to O78; Group B was unvaccinated but exposed to O78; Group C was vaccinated and exposed to O26; Group D was unvaccinated but exposed to O26. At 14 days old, chickens in groups A and C received a single dose of the vaccine, while groups B and D received normal saline subcutaneously. At 35 days old, all groups were challenged with O78 and O26 as described above. Clinical signs and lesions, isolation of the bacterium, weight gain, food intake, FCR, and antibody titers against the O antigens of the vaccine strains and O26 were recorded. The results indicated that 2 weeks post-vaccination, titers to the O antigens of the vaccine strains were significantly higher in the vaccinated groups than in the unvaccinated groups (p ≤ 0.05). Following the challenge, no significant difference was observed in food intake and FCR between the groups (p > 0.05); however, the growth rate in group A was significantly higher than in group B (p ≤ 0.05). At 42-49 days old, the vaccinated groups had the highest growth rate, which was statistically significant compared to the unvaccinated groups; and FCR in group A was significantly better than in group B (p ≤ 0.05). In conclusion, it appears that in addition to homologous immunity, the vaccine also induces cross-immunity against O26.

Keywords

Main Subjects


1.    Dziva F, Stevens MP. Colibacillosis in poultry: unravelling the molecular basis of virulence of avian pathogenic Escherichia coli in their natural hosts. Avian Pathology. 2008; 37(4):355-66. Doi: 10.1080/03079450802216652. 
2.    Dhama K, Chakraborty S, Barathidasan R, Tiwari R, Rajagunalan S, Singh SD. Escherichia coli, an economically important avian pathogen, its disease manifestations, diagnosis and control, and public health significance: A review. Research Opinions in Animal and Veterinary Sciences. 2013; 3(6):179-94. 
3.    Nolan LK, Vaillancourt JP, Nicolle LB, Logue CM. Colibacillosis. In: Swayne DE, Boulianne M, Logue CM, Mcdougald LR, Nair V, Suarez DL. Diseases of poultry. 14th edition. Blackwell Publishing. 2020; 770-830. 
4.    Matthijs MG, Van Eck JH, Landman WJ, Stegeman JA. Ability of Massachusetts-type infectious bronchitis virus to increase colibacillosis susceptibility in commercial broilers: a comparison between vaccine and virulent field virus. Avian Pathology. 2003; 32(5):473-81. Doi: 10.1080/0307945031000154062.
5.    Barbour EK, Mastori FA, Shaib HA, Yaghi RH, Tayeb IT, Sleiman FT, Kassaify ZG, Sawaya RK, Nour AM, Sabra AH, Harakeh S. Efficacy of a Nutrient Synergy Against Colibacillosis in Poultry. International Journal of Applied Research in Veterinary Medicine. 2009; 7(1-2):43-9.  
6.    Kwaga JK, Allan BJ, Van der Hurk JV, Seida H, Potter AA. A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys. Infection and immunity. 1994; 62(9):3766-72. Doi: 10.1128/iai.62.9.3766-3772.1994.  
7.    Melamed D, Leitner G, Heller ED. A vaccine against avian colibacillosis based on ultrasonic inactivation of Escherichia coli. Avian diseases. 1991; 17-22. 
8.    Hem SL, HogenEsch H. Aluminum-containing adjuvants: properties, formulation, and use. In: Singh M. Vaccine adjuvants and delivery systems.  Hoboken, NJ: John Wiley & Sons inc. 2007; 81-114. 
9.    Gupa RK, RK,  Rost BE. Aluminum compounds as vaccine adjuvants. In: O'Hagan DT. Vaccine adjuvants. Springer New York: HumanaPress. 2000; 65-89. 
10.    Kholdi S, Motamedifar M, Fani F, Mohebi S, Bazargani A. Virulence factors, serogroups, and antibiotic resistance of Shiga-toxin producing Escherichia coli from raw beef, chicken meat, and vegetables in Southwest Iran. Iranian Journal of Veterinary Research. 2021; 22(3):180-187. Doi: 10.22099/IJVR.2021.39266.5706. 
11.    Rahman MM, Husna A, Elshabrawy HA, Alam J, Runa NY, Badruzzaman AT, Banu NA, Al Mamun M, Paul B, Das S, Rahman MM. Isolation and molecular characterization of multidrug-resistant Escherichia coli from chicken meat. Scientific Reports. 2020;10(1):21999. Doi:10.1038/s41598-020-78367-2. 
12.    Tairov J, Salimov K. Cultural, biochemical, and pathogenic properties of Escherichia coli isolated from birds. InE3S Web of Conferences 2023 (Vol. 452, p. 01023). EDP Sciences. Doi:10.1051/e3sconf/202345201023.
13.    Kathayat D, Lokesh D, Ranjit S, Rajashekara G. Avian Pathogenic Escherichia coli (APEC): An Overview of Virulence and Pathogenesis Factors, Zoonotic Potential, and Control Strategies. Pathogens. 2021; 10(4):467.Doi/10.3390/pathogens10040467.
14.    Elnagar R, Elkenany R, Younis G. Interleukin gene expression in broiler chickens infected by different Escherichia coli serotypes. Veterinary World. 2021; 14(10):2727-2734. Doi: 10.14202/vetworld.2021.2727-2734.
15.    Lutful Kabir SM. Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. International journal of environmental research and public health. 2010; 7(1):89-114. Doi: 10.3390/ijerph7010089.
16.    Hu J, Afayibo DJ, Zhang B, Zhu H, Yao L, Guo W, Wang X, Wang Z, Wang D, Peng H, Tian M. Characteristics, pathogenic mechanism, zoonotic potential, drug resistance, and prevention of avian pathogenic Escherichia coli (APEC). Frontiers in Microbiology. 2022; 13:1049391. Doi: 10.3389/fmicb.2022.1049391.
17.    Pham VH, Abbas W, Huang J, Guo F, Zhang K, Kong L, Zhen W, Guo Y, Wang Z. Dietary coated essential oil and organic acid mixture supplementation improves health of broilers infected with avian pathogenic Escherichia coli. Animal Nutrition. 2023; 12:245-62. Doi: 10.1016/j.aninu.2022.09.010.
18.    El-Tahawy AO, Said AA, Shams GA, Hassan HM, Hassan AM, Amer SA, El-Nabtity SM. Evaluation of cefquinome's efficacy in controlling avian colibacillosis and detection of its residues using high performance liquid chromatography (HPLC). Saudi Journal of Biological Sciences. 2022; 29(5):3502-10. Doi:10.1016/j.sjbs.2022.02.029. 
19.    Amen O, El Hendy AH, Elfeil WK, Hussein AG. Evaluating the efficacy of commercial Escherichia coli killed vaccine in broiler chickens. Journal of Advanced Veterinary Research. 2023; 13 (6):1037-43.
20.    Liu B, Furevi A, Perepelov AV, Guo X, Cao H, Wang Q, Reeves PR, Knirel YA, Wang L, Widmalm G. Structure and genetics of Escherichia coli O antigens. FEMS microbiology reviews. 2020; 44(6):655-83. Doi: 10.1093/femsre/fuz028. 
21.    Paudel S, Apostolakos I, Vougat Ngom R, Tilli G, de Carvalho Ferreira HC, Piccirillo A. A systematic review and meta-analysis on the efficacy of vaccination against colibacillosis in broiler production. Plos one. 2024; 19(3):e0301029.
22.    Melamed D, Leitner G, Heller ED. A vaccine against avian colibacillosis based on ultrasonic inactivation of Escherichia coli. Avian diseases. 1991; 1:17-22. Doi: 10.2307/1591289. 
23.    Lee, MD and Arp, LH (1998). Colibacillosis.In: Swayne, DE; Glisson, JR; Jackwood, MW; Pearson, JE; Reed, WM; editors.Isolation and identification of avian pathogens.4th ed. American Association of Avian Pathologists. 14-16. 
24.    Gibbs PS, Petermann SR, Wooley RE. Comparison of several challenge models for studies in avian colibacillosis. Avian diseases. 2004; 48(4):751-8. Doi: 10.1637/7176-030404R.   
CAPTCHA Image
Volume 16, Issue 3 - Serial Number 36
This issue XML files are being prepared.
September 2024
Pages 92-98
  • Receive Date: 03 March 2024
  • Revise Date: 31 August 2024
  • Accept Date: 31 August 2024